📊 GLUC Key Takeaways
Is GLUC a Good Investment? Thesis Analysis
Glucose Health exhibits technical insolvency with negative stockholders equity of -$426.2K against minimal assets of $26.4K, coupled with negative operating cash flow and critically inadequate liquidity. The company cannot meet short-term obligations (current ratio 0.06x) and burns cash operationally despite marginal revenue. Most critically, financial data is stale (Sept 2017), suggesting company inactivity or abandonment.
While revenue has surged from a low base and gross margins are strong, the company remains loss-making at the operating level with negative operating cash flow. Severe liquidity stress (current ratio ~0.06x) and negative equity signal going‑concern risk, and the positive net income appears driven by non‑operating items rather than sustainable profits.
Why Buy GLUC? Key Strengths
- Gross margin of 78.5% indicates product-level profitability when revenue is generated
- Extreme revenue growth of 7232% YoY demonstrates demand response from minimal base
- Minimal debt burden with no long-term debt obligations
- Explosive YoY revenue growth from a small base
- High gross margin (78.5%) indicating attractive unit economics
- Reported net income positive this period (non-operating driven)
GLUC Investment Risks to Consider
- Technical insolvency: negative equity of -$426.2K indicates liabilities exceed assets by material amount
- Critical liquidity crisis: current ratio of 0.06x means company cannot cover short-term obligations
- Negative operating cash flow of -$13.9K with only $16.6K cash reserves indicates unsustainable burn rate
- Financial data is 9 years old (Sept 2017), indicating company abandonment or dormancy
- Net income positivity appears driven by non-operating items, not sustainable operations
- Micro-scale revenue base of $72.9K provides no margin for error
- Severe liquidity and solvency risk: negative equity and 0.06x current ratio
- Operating loss with negative operating cash flow; interest coverage negative
- Tiny scale and likely revenue volatility; profitability dependent on non-operating items
Key Metrics to Watch
- Stockholders equity trajectory and path to positive territory
- Operating cash flow sustainability and monthly burn rate
- Current liquidity position and ability to meet liabilities
- Revenue stability and customer retention post-growth spike
- Operating cash flow
- Current ratio (net working capital)
GLUC Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
GLUC Profitability Ratios
GLUC vs Default Sector
How Glucose Health, Inc. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GLUC Overvalued or Undervalued?
Based on fundamental analysis, Glucose Health, Inc. has mixed fundamental signals relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GLUC Balance Sheet & Liquidity
GLUC 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Glucose Health, Inc.'s revenue has grown significantly by 12,919% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.14 indicates the company is currently unprofitable.
GLUC Growth Metrics (YoY)
GLUC Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2017 | $2.1K | $18.8K | $0.00 |
| Q2 2017 | $34.0K | $20.2K | $0.01 |
| Q1 2017 | $120 | -$29.0K | $-0.01 |
| Q3 2016 | $2.1K | -$49.3K | $-0.02 |
| Q2 2016 | $552 | -$50.0K | $-0.03 |
| Q1 2016 | $25 | -$29.3K | $-0.01 |
| Q3 2015 | $2.1K | -$49.3K | $-0.02 |
| Q2 2015 | $442 | -$50.0K | $-0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GLUC Capital Allocation
GLUC SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Glucose Health, Inc. (CIK: 0001420108)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GLUC
What is the AI rating for GLUC?
Glucose Health, Inc. (GLUC) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GLUC's key strengths?
Claude: Gross margin of 78.5% indicates product-level profitability when revenue is generated. Extreme revenue growth of 7232% YoY demonstrates demand response from minimal base. ChatGPT: Explosive YoY revenue growth from a small base. High gross margin (78.5%) indicating attractive unit economics.
What are the risks of investing in GLUC?
Claude: Technical insolvency: negative equity of -$426.2K indicates liabilities exceed assets by material amount. Critical liquidity crisis: current ratio of 0.06x means company cannot cover short-term obligations. ChatGPT: Severe liquidity and solvency risk: negative equity and 0.06x current ratio. Operating loss with negative operating cash flow; interest coverage negative.
What is GLUC's revenue and growth?
Glucose Health, Inc. reported revenue of $72.9K.
Does GLUC pay dividends?
Glucose Health, Inc. does not currently pay dividends.
Where can I find GLUC SEC filings?
Official SEC filings for Glucose Health, Inc. (CIK: 0001420108) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GLUC's EPS?
Glucose Health, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GLUC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Glucose Health, Inc. has a STRONG SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GLUC stock overvalued or undervalued?
Valuation metrics for GLUC: ROE of N/A (sector avg: 15%), net margin of 53.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GLUC stock in 2026?
Our dual AI analysis gives Glucose Health, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is GLUC's free cash flow?
Glucose Health, Inc.'s operating cash flow is $-13.9K, with capital expenditures of N/A. FCF margin is -19.1%.
How does GLUC compare to other Default stocks?
Vs Default sector averages: Net margin 53.5% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.06 (avg: 1.8).